T1	p 70 159	postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy ]
T2	p 345 367	rectal cancer patients
T3	p 381 399	capecitabine-based
T4	p 450 566	Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without
T5	p 691 728	Two hundred and twenty-eight patients
T6	p 742 746	with
T7	p 806 809	172
T8	p 1373 1408	136 patients presented severe AEs .
T9	p 2554 2580	III rectal cancer patients
T10	i 24 42	A870G polymorphism
T11	i 120 161	adjuvant concurrent chemoradiotherapy ] .
T12	i 241 294	single nucleotide polymorphism ( SNP ) of CCND1 A870G
T13	i 305 327	adverse events ( AEs )
T14	i 381 441	capecitabine-based postoperative chemoradiotherapy ( CRT ) .
T15	i 517 613	postoperative CRT of capecitabine with or without oxaliplatin were accumulated and prostectively
T16	i 747 799	concurrent capecitabine and radiotherapy ( Cap-CRT )
T17	i 832 901	with capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT ) .
T18	i 1205 1208	SNP
T19	i 2440 2452	polymorphism
T20	i 2594 2665	adjuvant concurrent chemoradiotherapy of capecitabine and oxaliplatin .
T21	o 46 66	acute adverse events
T22	o 902 916	Adverse events
T23	o 978 992	Adverse Events
T24	o 1096 1110	reaction-based
T25	o 1123 1164	fragment length polymorphism ( PCR-RFLP )
T26	o 1213 1218	acute
T27	o 1464 1473	GA and AA
T28	o 1606 1614	Diarrhea
T29	o 1644 1659	severe diarrhea
T30	o 1691 1702	frequencies
T31	o 1716 1740	genotypes GG , GA and AA
T32	o 1884 1892	diarrhea
T33	o 1966 1990	risk for severe diarrhea
T34	o 2225 2244	for severe diarrhea
T35	o 2398 2415	severe diarrhea .